Dermatologic drugs in pregnancy
Identifieur interne : 000297 ( Istex/Corpus ); précédent : 000296; suivant : 000298Dermatologic drugs in pregnancy
Auteurs : Monica Bologa ; Anne Pastuszak ; Neil H. Shear ; Gideon KorenSource :
- Clinics in Dermatology [ 0738-081X ] ; 1991.
English descriptors
- Teeft :
- Acetylsalicylic acid, Acitretin, Acne, Acyclovir, Adverse effects, Animal studies, Antihistamine, Antimalarial, Antimicrobial, Appl, Appl pharmacol, Baseline, Baseline risk, Birth defects, Bologa, Bologa clinics, Boric acid, Case report, Case reports, Chemotherapy, Chloroquine, Cleft, Cleft palate, Clin, Clin pharmacol, Clindamycin, Clinic, Clinical pharmacology, Congenital, Congenital defects, Congenital malformations, Corticosteroid, Defect, Dermatol, Dermatologic, Dermatology, Dermatology dermatologic, Dos, Early pregnancy, Elective abortions, Erythromycin, Etretinate, Experimental studies, Fatal poisoning, Fetal, Fetal development, Fetus, First trimester, General population, Gentamicin, Gestation, Gestational exposure, Griseofulvin, Gynecol, Hexachlorophene, High doses, Human reports, Human teratogenicity, Hydroxyzine, Inadvertent, Inadvertent exposure, Intrauterine exposure, Isotretinoin, Ketoconazole, Lancet, Large categories, Late pregnancy, Liveborn infants, Major malformations, Malformation, Malformation rate, Malformed infants, Maternal ingestion, Methotrexate, Miconazole, Minor malformations, Motherisk program, Mucous membranes, Multiple malformations, Mycosis fungoides, Neonatal, Neonate, Obstet, Obstet gynecol, Palate, Pediatr, Penicillin, Percutaneous, Percutaneous absorption, Pharmacol, Placenta, Placental transfer, Potential risk, Pregnancy, Pregnant patient, Pregnant women, Prospective study, Psoriasis, Relative risk, Reproductive, Reproductive toxicity, Retinoid, Retinol, Rheumatoid arthritis, Salicylic acid, Severe psoriasis, Sick children, Significant association, Spontaneous abortions, Sulfonamide, Teratogen, Teratogenic, Teratogenic effects, Teratogenic risk, Teratogenicity, Teratological studies, Teratology, Tetracycline, Third trimesters, Topical, Topical application, Topical preparations, Topically, Toxicity, Trimester, Ultrasound, Utero, Utero exposure, Vulvovaginal candidiasis, Warrant pregnancy termination.
Abstract
Abstract: Since the thalidomide disaster, there has been increasing concern about the association of therapeutic agents with teratogenicity. Although teratogenicity of thalidomide is now well defined,1 use of the drug is considered safe in nonpregnant patients and has proven useful in the treatment of leprosy reactions and a variety of skin diseases.2,3 Nevertheless, association with birth defects resulted in removal of the drug from the market, which has made it virtually unavailable. Twenty years after the thalidomide disaster, association of the use of 13-cis-retinoic acid in pregnancy with a well-defined syndrome of birth defects has renewed concerns about the teratogenic risk of all drugs in pregnancy.4
Url:
DOI: 10.1016/0738-081X(91)90072-S
Links to Exploration step
ISTEX:13EC5A1437D79446E780E3FDFC85FA1230D537CFLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Dermatologic drugs in pregnancy</title><author><name sortKey="Bologa, Monica" sort="Bologa, Monica" uniqKey="Bologa M" first="Monica" last="Bologa">Monica Bologa</name><affiliation><mods:affiliation>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Currently with The Upjohn Company of Canada, Canada</mods:affiliation></affiliation></author><author><name sortKey="Pastuszak, Anne" sort="Pastuszak, Anne" uniqKey="Pastuszak A" first="Anne" last="Pastuszak">Anne Pastuszak</name><affiliation><mods:affiliation>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</mods:affiliation></affiliation></author><author><name sortKey="Shear, Neil H" sort="Shear, Neil H" uniqKey="Shear N" first="Neil H." last="Shear">Neil H. Shear</name><affiliation><mods:affiliation>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Career Scientists at the Ontario Ministry of Health, Canada</mods:affiliation></affiliation></author><author><name sortKey="Koren, Gideon" sort="Koren, Gideon" uniqKey="Koren G" first="Gideon" last="Koren">Gideon Koren</name><affiliation><mods:affiliation>Address correspondence to: Gideon Koren, MD, FRPC, Division of Clinical Pharmacology, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.</mods:affiliation></affiliation><affiliation><mods:affiliation>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Career Scientists at the Ontario Ministry of Health, Canada</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:13EC5A1437D79446E780E3FDFC85FA1230D537CF</idno><date when="1991" year="1991">1991</date><idno type="doi">10.1016/0738-081X(91)90072-S</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-1M4MK031-4/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000297</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000297</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Dermatologic drugs in pregnancy</title><author><name sortKey="Bologa, Monica" sort="Bologa, Monica" uniqKey="Bologa M" first="Monica" last="Bologa">Monica Bologa</name><affiliation><mods:affiliation>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Currently with The Upjohn Company of Canada, Canada</mods:affiliation></affiliation></author><author><name sortKey="Pastuszak, Anne" sort="Pastuszak, Anne" uniqKey="Pastuszak A" first="Anne" last="Pastuszak">Anne Pastuszak</name><affiliation><mods:affiliation>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</mods:affiliation></affiliation></author><author><name sortKey="Shear, Neil H" sort="Shear, Neil H" uniqKey="Shear N" first="Neil H." last="Shear">Neil H. Shear</name><affiliation><mods:affiliation>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Career Scientists at the Ontario Ministry of Health, Canada</mods:affiliation></affiliation></author><author><name sortKey="Koren, Gideon" sort="Koren, Gideon" uniqKey="Koren G" first="Gideon" last="Koren">Gideon Koren</name><affiliation><mods:affiliation>Address correspondence to: Gideon Koren, MD, FRPC, Division of Clinical Pharmacology, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.</mods:affiliation></affiliation><affiliation><mods:affiliation>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Career Scientists at the Ontario Ministry of Health, Canada</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinics in Dermatology</title><title level="j" type="abbrev">CID</title><idno type="ISSN">0738-081X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1991">1991</date><biblScope unit="volume">9</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="435">435</biblScope><biblScope unit="page" to="451">451</biblScope></imprint><idno type="ISSN">0738-081X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0738-081X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acetylsalicylic acid</term><term>Acitretin</term><term>Acne</term><term>Acyclovir</term><term>Adverse effects</term><term>Animal studies</term><term>Antihistamine</term><term>Antimalarial</term><term>Antimicrobial</term><term>Appl</term><term>Appl pharmacol</term><term>Baseline</term><term>Baseline risk</term><term>Birth defects</term><term>Bologa</term><term>Bologa clinics</term><term>Boric acid</term><term>Case report</term><term>Case reports</term><term>Chemotherapy</term><term>Chloroquine</term><term>Cleft</term><term>Cleft palate</term><term>Clin</term><term>Clin pharmacol</term><term>Clindamycin</term><term>Clinic</term><term>Clinical pharmacology</term><term>Congenital</term><term>Congenital defects</term><term>Congenital malformations</term><term>Corticosteroid</term><term>Defect</term><term>Dermatol</term><term>Dermatologic</term><term>Dermatology</term><term>Dermatology dermatologic</term><term>Dos</term><term>Early pregnancy</term><term>Elective abortions</term><term>Erythromycin</term><term>Etretinate</term><term>Experimental studies</term><term>Fatal poisoning</term><term>Fetal</term><term>Fetal development</term><term>Fetus</term><term>First trimester</term><term>General population</term><term>Gentamicin</term><term>Gestation</term><term>Gestational exposure</term><term>Griseofulvin</term><term>Gynecol</term><term>Hexachlorophene</term><term>High doses</term><term>Human reports</term><term>Human teratogenicity</term><term>Hydroxyzine</term><term>Inadvertent</term><term>Inadvertent exposure</term><term>Intrauterine exposure</term><term>Isotretinoin</term><term>Ketoconazole</term><term>Lancet</term><term>Large categories</term><term>Late pregnancy</term><term>Liveborn infants</term><term>Major malformations</term><term>Malformation</term><term>Malformation rate</term><term>Malformed infants</term><term>Maternal ingestion</term><term>Methotrexate</term><term>Miconazole</term><term>Minor malformations</term><term>Motherisk program</term><term>Mucous membranes</term><term>Multiple malformations</term><term>Mycosis fungoides</term><term>Neonatal</term><term>Neonate</term><term>Obstet</term><term>Obstet gynecol</term><term>Palate</term><term>Pediatr</term><term>Penicillin</term><term>Percutaneous</term><term>Percutaneous absorption</term><term>Pharmacol</term><term>Placenta</term><term>Placental transfer</term><term>Potential risk</term><term>Pregnancy</term><term>Pregnant patient</term><term>Pregnant women</term><term>Prospective study</term><term>Psoriasis</term><term>Relative risk</term><term>Reproductive</term><term>Reproductive toxicity</term><term>Retinoid</term><term>Retinol</term><term>Rheumatoid arthritis</term><term>Salicylic acid</term><term>Severe psoriasis</term><term>Sick children</term><term>Significant association</term><term>Spontaneous abortions</term><term>Sulfonamide</term><term>Teratogen</term><term>Teratogenic</term><term>Teratogenic effects</term><term>Teratogenic risk</term><term>Teratogenicity</term><term>Teratological studies</term><term>Teratology</term><term>Tetracycline</term><term>Third trimesters</term><term>Topical</term><term>Topical application</term><term>Topical preparations</term><term>Topically</term><term>Toxicity</term><term>Trimester</term><term>Ultrasound</term><term>Utero</term><term>Utero exposure</term><term>Vulvovaginal candidiasis</term><term>Warrant pregnancy termination</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Since the thalidomide disaster, there has been increasing concern about the association of therapeutic agents with teratogenicity. Although teratogenicity of thalidomide is now well defined,1 use of the drug is considered safe in nonpregnant patients and has proven useful in the treatment of leprosy reactions and a variety of skin diseases.2,3 Nevertheless, association with birth defects resulted in removal of the drug from the market, which has made it virtually unavailable. Twenty years after the thalidomide disaster, association of the use of 13-cis-retinoic acid in pregnancy with a well-defined syndrome of birth defects has renewed concerns about the teratogenic risk of all drugs in pregnancy.4</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>malformation</json:string><json:string>teratogenic</json:string><json:string>baseline risk</json:string><json:string>teratogenicity</json:string><json:string>birth defects</json:string><json:string>fetal</json:string><json:string>dermatology</json:string><json:string>pregnancy</json:string><json:string>etretinate</json:string><json:string>obstet</json:string><json:string>corticosteroid</json:string><json:string>gynecol</json:string><json:string>toxicity</json:string><json:string>fetus</json:string><json:string>bologa</json:string><json:string>griseofulvin</json:string><json:string>baseline</json:string><json:string>pharmacol</json:string><json:string>obstet gynecol</json:string><json:string>topically</json:string><json:string>teratogen</json:string><json:string>hexachlorophene</json:string><json:string>acne</json:string><json:string>retinoid</json:string><json:string>dermatologic</json:string><json:string>minor malformations</json:string><json:string>isotretinoin</json:string><json:string>gentamicin</json:string><json:string>methotrexate</json:string><json:string>acitretin</json:string><json:string>pregnant women</json:string><json:string>teratology</json:string><json:string>defect</json:string><json:string>ketoconazole</json:string><json:string>lancet</json:string><json:string>chemotherapy</json:string><json:string>clindamycin</json:string><json:string>acyclovir</json:string><json:string>gestation</json:string><json:string>animal studies</json:string><json:string>topical application</json:string><json:string>pediatr</json:string><json:string>congenital</json:string><json:string>antimicrobial</json:string><json:string>miconazole</json:string><json:string>case reports</json:string><json:string>tetracycline</json:string><json:string>chloroquine</json:string><json:string>dermatol</json:string><json:string>ultrasound</json:string><json:string>placenta</json:string><json:string>erythromycin</json:string><json:string>large categories</json:string><json:string>appl</json:string><json:string>psoriasis</json:string><json:string>trimester</json:string><json:string>congenital malformations</json:string><json:string>teratogenic risk</json:string><json:string>antihistamine</json:string><json:string>retinol</json:string><json:string>first trimester</json:string><json:string>neonate</json:string><json:string>percutaneous</json:string><json:string>hydroxyzine</json:string><json:string>inadvertent exposure</json:string><json:string>clin</json:string><json:string>utero</json:string><json:string>spontaneous abortions</json:string><json:string>sulfonamide</json:string><json:string>antimalarial</json:string><json:string>topical</json:string><json:string>case report</json:string><json:string>cleft palate</json:string><json:string>reproductive</json:string><json:string>pregnant patient</json:string><json:string>appl pharmacol</json:string><json:string>teratogenic effects</json:string><json:string>congenital defects</json:string><json:string>early pregnancy</json:string><json:string>dos</json:string><json:string>warrant pregnancy termination</json:string><json:string>reproductive toxicity</json:string><json:string>maternal ingestion</json:string><json:string>clin pharmacol</json:string><json:string>potential risk</json:string><json:string>motherisk program</json:string><json:string>placental transfer</json:string><json:string>human reports</json:string><json:string>bologa clinics</json:string><json:string>salicylic acid</json:string><json:string>experimental studies</json:string><json:string>percutaneous absorption</json:string><json:string>relative risk</json:string><json:string>penicillin</json:string><json:string>neonatal</json:string><json:string>malformed infants</json:string><json:string>third trimesters</json:string><json:string>high doses</json:string><json:string>general population</json:string><json:string>fatal poisoning</json:string><json:string>utero exposure</json:string><json:string>intrauterine exposure</json:string><json:string>acetylsalicylic acid</json:string><json:string>dermatology dermatologic</json:string><json:string>fetal development</json:string><json:string>vulvovaginal candidiasis</json:string><json:string>human teratogenicity</json:string><json:string>severe psoriasis</json:string><json:string>clinical pharmacology</json:string><json:string>multiple malformations</json:string><json:string>rheumatoid arthritis</json:string><json:string>mycosis fungoides</json:string><json:string>liveborn infants</json:string><json:string>boric acid</json:string><json:string>significant association</json:string><json:string>elective abortions</json:string><json:string>gestational exposure</json:string><json:string>malformation rate</json:string><json:string>topical preparations</json:string><json:string>mucous membranes</json:string><json:string>sick children</json:string><json:string>late pregnancy</json:string><json:string>major malformations</json:string><json:string>prospective study</json:string><json:string>adverse effects</json:string><json:string>teratological studies</json:string><json:string>clinic</json:string><json:string>cleft</json:string><json:string>inadvertent</json:string><json:string>palate</json:string></teeft></keywords><author><json:item><name>Monica Bologa MD</name><affiliations><json:string>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</json:string><json:string>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</json:string><json:string>Currently with The Upjohn Company of Canada, Canada</json:string></affiliations></json:item><json:item><name>Anne Pastuszak MSC</name><affiliations><json:string>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</json:string><json:string>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</json:string></affiliations></json:item><json:item><name>Neil H. Shear MD, FRCPC</name><affiliations><json:string>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</json:string><json:string>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</json:string><json:string>Career Scientists at the Ontario Ministry of Health, Canada</json:string></affiliations></json:item><json:item><name>Gideon Koren MD, FRCPC</name><affiliations><json:string>Address correspondence to: Gideon Koren, MD, FRPC, Division of Clinical Pharmacology, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.</json:string><json:string>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</json:string><json:string>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</json:string><json:string>Career Scientists at the Ontario Ministry of Health, Canada</json:string></affiliations></json:item></author><arkIstex>ark:/67375/6H6-1M4MK031-4</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Abstract: Since the thalidomide disaster, there has been increasing concern about the association of therapeutic agents with teratogenicity. Although teratogenicity of thalidomide is now well defined,1 use of the drug is considered safe in nonpregnant patients and has proven useful in the treatment of leprosy reactions and a variety of skin diseases.2,3 Nevertheless, association with birth defects resulted in removal of the drug from the market, which has made it virtually unavailable. Twenty years after the thalidomide disaster, association of the use of 13-cis-retinoic acid in pregnancy with a well-defined syndrome of birth defects has renewed concerns about the teratogenic risk of all drugs in pregnancy.4</abstract><qualityIndicators><score>8.272</score><pdfWordCount>10831</pdfWordCount><pdfCharCount>72814</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>17</pdfPageCount><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>106</abstractWordCount><abstractCharCount>717</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Dermatologic drugs in pregnancy</title><pmid><json:string>1688017</json:string></pmid><pii><json:string>0738-081X(91)90072-S</json:string></pii><genre><json:string>research-article</json:string></genre><serie><title>Fed Proc</title><language><json:string>unknown</json:string></language><volume>34</volume><pages><first>1661</first><last>1665</last></pages></serie><host><title>Clinics in Dermatology</title><language><json:string>unknown</json:string></language><publicationDate>1991</publicationDate><issn><json:string>0738-081X</json:string></issn><pii><json:string>S0738-081X(00)X0083-1</json:string></pii><volume>9</volume><issue>4</issue><pages><first>435</first><last>451</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>10s</json:string><json:string>1982</json:string><json:string>1983</json:string><json:string>1991</json:string><json:string>1985</json:string></date><geogName></geogName><orgName><json:string>University of Toronto</json:string><json:string>Elsevier Science Publishing Co.</json:string><json:string>Division of Clinical Pharmacology</json:string><json:string>Research Institufe, Hospital for Sick Children, and Divisions</json:string><json:string>Hospital for Sick Children, Toronto</json:string><json:string>Hospital for Sick Children</json:string><json:string>Department of Pediatrics</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Drug</json:string><json:string>U.S. Food</json:string><json:string>Formulations</json:string><json:string>O Additional</json:string><json:string>Karen</json:string><json:string>Case</json:string><json:string>Gideon Karen</json:string><json:string>AL Table</json:string></persName><placeName><json:string>Tevatogenicity</json:string><json:string>Teratogenicity</json:string><json:string>Canada</json:string><json:string>Toronto</json:string><json:string>America</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Dermatology ET AL 1992</json:string><json:string>Dermatology ET AL 2992</json:string><json:string>Pregnancy and Lactation, 1986</json:string><json:string>O Bologa-Campeanu et al</json:string><json:string>Briggs et al</json:string><json:string>Heinonen et al</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-1M4MK031-4</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - dermatology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - dermatology & venereal diseases</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Dermatology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>1991</publicationDate><copyrightDate>1991</copyrightDate><doi><json:string>10.1016/0738-081X(91)90072-S</json:string></doi><id>13EC5A1437D79446E780E3FDFC85FA1230D537CF</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-1M4MK031-4/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-1M4MK031-4/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-1M4MK031-4/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">Dermatologic drugs in pregnancy</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>1991</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Dermatologic drugs in pregnancy</title><author xml:id="author-0000"><persName><forename type="first">Monica</forename><surname>Bologa</surname></persName><roleName type="degree">MD</roleName><affiliation>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</affiliation><affiliation>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</affiliation><affiliation>Currently with The Upjohn Company of Canada, Canada</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Anne</forename><surname>Pastuszak</surname></persName><roleName type="degree">MSC</roleName><affiliation>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</affiliation><affiliation>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Neil H.</forename><surname>Shear</surname></persName><roleName type="degree">MD, FRCPC</roleName><affiliation>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</affiliation><affiliation>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</affiliation><affiliation>Career Scientists at the Ontario Ministry of Health, Canada</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Gideon</forename><surname>Koren</surname></persName><roleName type="degree">MD, FRCPC</roleName><affiliation>Address correspondence to: Gideon Koren, MD, FRPC, Division of Clinical Pharmacology, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.</affiliation><affiliation>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</affiliation><affiliation>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</affiliation><affiliation>Career Scientists at the Ontario Ministry of Health, Canada</affiliation></author><idno type="istex">13EC5A1437D79446E780E3FDFC85FA1230D537CF</idno><idno type="ark">ark:/67375/6H6-1M4MK031-4</idno><idno type="DOI">10.1016/0738-081X(91)90072-S</idno><idno type="PII">0738-081X(91)90072-S</idno></analytic><monogr><title level="j">Clinics in Dermatology</title><title level="j" type="abbrev">CID</title><idno type="pISSN">0738-081X</idno><idno type="PII">S0738-081X(00)X0083-1</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1991"></date><biblScope unit="volume">9</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="435">435</biblScope><biblScope unit="page" to="451">451</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1991</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: Since the thalidomide disaster, there has been increasing concern about the association of therapeutic agents with teratogenicity. Although teratogenicity of thalidomide is now well defined,1 use of the drug is considered safe in nonpregnant patients and has proven useful in the treatment of leprosy reactions and a variety of skin diseases.2,3 Nevertheless, association with birth defects resulted in removal of the drug from the market, which has made it virtually unavailable. Twenty years after the thalidomide disaster, association of the use of 13-cis-retinoic acid in pregnancy with a well-defined syndrome of birth defects has renewed concerns about the teratogenic risk of all drugs in pregnancy.4</p></abstract></profileDesc><revisionDesc><change when="1991">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-1M4MK031-4/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>CID</jid><aid>9190072S</aid><ce:pii>0738-081X(91)90072-S</ce:pii><ce:doi>10.1016/0738-081X(91)90072-S</ce:doi><ce:copyright type="unknown" year="1991"></ce:copyright></item-info><head><ce:title>Dermatologic drugs in pregnancy</ce:title><ce:author-group><ce:author><ce:given-name>Monica</ce:given-name><ce:surname>Bologa</ce:surname><ce:degrees>MD</ce:degrees><ce:cross-ref refid="AFF1"><ce:sup>1</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup>2</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF3"><ce:sup>3</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Anne</ce:given-name><ce:surname>Pastuszak</ce:surname><ce:degrees>MSC</ce:degrees><ce:cross-ref refid="AFF1"><ce:sup>1</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup>2</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Neil H.</ce:given-name><ce:surname>Shear</ce:surname><ce:degrees>MD, FRCPC</ce:degrees><ce:cross-ref refid="AFF1"><ce:sup>1</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup>2</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF4"><ce:sup>4</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Gideon</ce:given-name><ce:surname>Koren</ce:surname><ce:degrees>MD, FRCPC</ce:degrees><ce:cross-ref refid="COR1"><ce:sup>∗</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF1"><ce:sup>1</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup>2</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF4"><ce:sup>4</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>1</ce:label><ce:textfn>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>2</ce:label><ce:textfn>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</ce:textfn></ce:affiliation><ce:affiliation id="AFF3"><ce:label>3</ce:label><ce:textfn>Currently with The Upjohn Company of Canada, Canada</ce:textfn></ce:affiliation><ce:affiliation id="AFF4"><ce:label>4</ce:label><ce:textfn>Career Scientists at the Ontario Ministry of Health, Canada</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Address correspondence to: Gideon Koren, MD, FRPC, Division of Clinical Pharmacology, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.</ce:text></ce:correspondence></ce:author-group><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>Since the thalidomide disaster, there has been increasing concern about the association of therapeutic agents with teratogenicity. Although teratogenicity of thalidomide is now well defined,<ce:sup>1</ce:sup> use of the drug is considered safe in nonpregnant patients and has proven useful in the treatment of leprosy reactions and a variety of skin diseases.<ce:sup>2,3</ce:sup> Nevertheless, association with birth defects resulted in removal of the drug from the market, which has made it virtually unavailable. Twenty years after the thalidomide disaster, association of the use of 13-<ce:italic>cis</ce:italic>-retinoic acid in pregnancy with a well-defined syndrome of birth defects has renewed concerns about the teratogenic risk of all drugs in pregnancy.<ce:sup>4</ce:sup></ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Dermatologic drugs in pregnancy</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Dermatologic drugs in pregnancy</title></titleInfo><name type="personal"><namePart type="given">Monica</namePart><namePart type="family">Bologa</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</affiliation><affiliation>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</affiliation><affiliation>Currently with The Upjohn Company of Canada, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anne</namePart><namePart type="family">Pastuszak</namePart><namePart type="termsOfAddress">MSC</namePart><affiliation>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</affiliation><affiliation>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Neil H.</namePart><namePart type="family">Shear</namePart><namePart type="termsOfAddress">MD, FRCPC</namePart><affiliation>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</affiliation><affiliation>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</affiliation><affiliation>Career Scientists at the Ontario Ministry of Health, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gideon</namePart><namePart type="family">Koren</namePart><namePart type="termsOfAddress">MD, FRCPC</namePart><affiliation>Address correspondence to: Gideon Koren, MD, FRPC, Division of Clinical Pharmacology, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.</affiliation><affiliation>From the Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and the Research Institute, Hospital for Sick Children, Canada</affiliation><affiliation>Divisions of Dermatology and Clinical Pharmacology, Sunnybrook Health Science Centre, Departments of Medicine, Pediatrics, and Pharmacology, University of Toronto, Toronto, Canada</affiliation><affiliation>Career Scientists at the Ontario Ministry of Health, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1991</dateIssued><copyrightDate encoding="w3cdtf">1991</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: Since the thalidomide disaster, there has been increasing concern about the association of therapeutic agents with teratogenicity. Although teratogenicity of thalidomide is now well defined,1 use of the drug is considered safe in nonpregnant patients and has proven useful in the treatment of leprosy reactions and a variety of skin diseases.2,3 Nevertheless, association with birth defects resulted in removal of the drug from the market, which has made it virtually unavailable. Twenty years after the thalidomide disaster, association of the use of 13-cis-retinoic acid in pregnancy with a well-defined syndrome of birth defects has renewed concerns about the teratogenic risk of all drugs in pregnancy.4</abstract><relatedItem type="host"><titleInfo><title>Clinics in Dermatology</title></titleInfo><titleInfo type="abbreviated"><title>CID</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1991</dateIssued></originInfo><identifier type="ISSN">0738-081X</identifier><identifier type="PII">S0738-081X(00)X0083-1</identifier><part><date>1991</date><detail type="volume"><number>9</number><caption>vol.</caption></detail><detail type="issue"><number>4</number><caption>no.</caption></detail><extent unit="issue-pages"><start>421</start><end>611</end></extent><extent unit="pages"><start>435</start><end>451</end></extent></part></relatedItem><identifier type="istex">13EC5A1437D79446E780E3FDFC85FA1230D537CF</identifier><identifier type="ark">ark:/67375/6H6-1M4MK031-4</identifier><identifier type="DOI">10.1016/0738-081X(91)90072-S</identifier><identifier type="PII">0738-081X(91)90072-S</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-1M4MK031-4/record.json</uri></json:item></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000297 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000297 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:13EC5A1437D79446E780E3FDFC85FA1230D537CF
|texte= Dermatologic drugs in pregnancy
}}
| This area was generated with Dilib version V0.6.33. |  |